Vicore Pharma Holding AB

VCRE

Healthcare|Biotechnology|Sweden

$14.01

-0.22 (-1.57%)

Tangible Book

$3.86

Clinical Trials (11)

Trial	Conditions	Phase	Status	Enrollment	Design	Drug
NCT06588686 A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.	Idiopathic Pulmonary Fibrosis (IPF)	P2	Active	378	RCT, Double-blind	Buloxibutid, Placebo
NCT04880642 A Trial to Investigate Recovery From COVID-19 With C21 in Adult Subjects	COVID-19	P3	Completed	272	RCT, Double-blind	C21, Placebo
NCT04452435 Safety and Efficacy of C21 in Subjects With COVID-19	COVID-19	P2	Completed	206	RCT, Double-blind	C21, Placebo
NCT04388176 Cold Challenge With C21 in RP	Raynaud Phenomenon, Systemic Sclerosis	P2	Completed	20	RCT, Double-blind	C21, C21, Placebo, Placebo
NCT04533022 Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPF	Idiopathic Pulmonary Fibrosis	P2	Completed	52	Open-label	C21
NCT05277922 Effect of C21 on Forearm Blood Flow	Study Vasodilatory Effects of C21	P1	Completed	5	Open-label	C21, Sodium Nitroprusside
NCT05831644 A Trial to Evaluate the Effect of C21 on Endothelial Dysfunction in Subjects With Type 2 Diabetes	Type2diabetes, Endothelial Dysfunction	P1	Completed	11	RCT, Double-blind	C21
NCT05830799 A Trial to Evaluate the Impact of C21 on the Exposure of 4 Substrates in Healthy Volunteers	Drug Interaction	P1	Completed	19	Open-label	Drug Drug Interaction
NCT05427253 First-in-human Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of C106 in Healthy Subjects	Safety Issues, Tolerance	P1	Completed	80	RCT, Double-blind	C106 solution, Placebo
NCT05330312 Controlled Investigation to Evaluate Impact of dCBT on Psychological Symptom Burden in Adult Subjects With PF	Pulmonary Fibrosis, Anxiety	N/A	Completed	119	RCT, Single-blind	—
NCT04878913 Retrospective Evaluation of Lung Pathology in Subjects With COVID-19	COVID-19, COVID-19 Pneumonia		Completed	35	—	C21, Placebo